Adreno Pharmaceuticals Private Limited
Pharmaceutical company trading medicines and related equipment, incorporated in 2016.
2016 | Delhi (India) | Active
Adreno Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 8 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.64 M
- Revenue Growth 68.18%
- Profit Growth 204.11%
- Ebitda 300.70%
- Net Worth 1.54%
- Total Assets -31.89%
About Adreno Pharmaceuticals
Adreno Pharmaceuticals Private Limited (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 08 September 2016 (Eight years and five months 20 days old ). Its registered office is in Delhi, India.
The Corporate was formerly known as Adreno Pharmacuticals Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹0.64 M.
Prasenjit Nandi and Kabita Roy serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U33100DL2016PTC305661
- Company No.
305661
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Sep 2016
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Pharma
Healthcare
Who are the key members and board of directors at Adreno Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Prasenjit Nandi  | Director | 08-Sep-2016 | Current |
| Kabita Roy | Director | 04-Jun-2019 | Current |
Financial Performance of Adreno Pharmaceuticals.
Adreno Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 68.18% increase. The company also saw a substantial improvement in profitability, with a 204.11% increase in profit. The company's net worth moved up by a moderate rise of 1.54%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Adreno Pharmaceuticals?
In 2022, Adreno Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
Open Charges
₹0.64 M
Satisfied Charges
₹0
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 0.06 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 03 Nov 2023 | Hdfc Bank Limited | ₹0.64 M | Open |
How Many Employees Work at Adreno Pharmaceuticals?
Unlock and access historical data on people associated with Adreno Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Adreno Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Adreno Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
